Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

NCT03643107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer Patients

Interventions

DRUG: Irofulven
COMBINATION_PRODUCT: Prednisolone 10 mg

Sponsor

Allarity Therapeutics

Collaborators

[object Object]
[object Object]